|
Name |
Versixanthone F
|
| Molecular Formula | C33H34O15 | |
| IUPAC Name* |
methyl (3S,4R,4aR)-4,8,9-trihydroxy-7-[(2S)-5-hydroxy-2-[(1R,2S)-1-hydroxy-4-methoxy-2-methyl-4-oxobutyl]-2-methoxycarbonyl-4-oxo-3H-chromen-6-yl]-3-methyl-1-oxo-3,4-dihydro-2H-xanthene-4a-carboxylate
|
|
| SMILES |
C[C@H]1CC(=O)C2=C(C3=C(C=CC(=C3O)C4=C(C5=C(C=C4)O[C@@](CC5=O)([C@@H]([C@@H](C)CC(=O)OC)O)C(=O)OC)O)O[C@]2([C@@H]1O)C(=O)OC)O
|
|
| InChI |
InChI=1S/C33H34O15/c1-13-10-17(34)24-27(39)23-20(48-33(24,29(13)41)31(43)46-5)9-7-16(26(23)38)15-6-8-19-22(25(15)37)18(35)12-32(47-19,30(42)45-4)28(40)14(2)11-21(36)44-3/h6-9,13-14,28-29,37-41H,10-12H2,1-5H3/t13-,14-,28+,29+,32-,33+/m0/s1
|
|
| InChIKey |
SQSNPCJTBKSTEC-ZSIZJZIHSA-N
|
|
| Synonyms |
Versixanthone F; CHEMBL3739578; J3.514.045J
|
|
| CAS | NA | |
| PubChem CID | 127039736 | |
| ChEMBL ID | CHEMBL3739578 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 670.6 | ALogp: | 2.7 |
| HBD: | 5 | HBA: | 15 |
| Rotatable Bonds: | 10 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 233.0 | Aromatic Rings: | 5 |
| Heavy Atoms: | 48 | QED Weighted: | 0.21 |
| Caco-2 Permeability: | -5.862 | MDCK Permeability: | 0.00001390 |
| Pgp-inhibitor: | 0.479 | Pgp-substrate: | 0.774 |
| Human Intestinal Absorption (HIA): | 0.762 | 20% Bioavailability (F20%): | 0.015 |
| 30% Bioavailability (F30%): | 0.971 |
| Blood-Brain-Barrier Penetration (BBB): | 0.026 | Plasma Protein Binding (PPB): | 79.58% |
| Volume Distribution (VD): | 1.016 | Fu: | 15.30% |
| CYP1A2-inhibitor: | 0.012 | CYP1A2-substrate: | 0.803 |
| CYP2C19-inhibitor: | 0.022 | CYP2C19-substrate: | 0.17 |
| CYP2C9-inhibitor: | 0.05 | CYP2C9-substrate: | 0.158 |
| CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.137 |
| CYP3A4-inhibitor: | 0.725 | CYP3A4-substrate: | 0.313 |
| Clearance (CL): | 6.348 | Half-life (T1/2): | 0.069 |
| hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.903 |
| Drug-inuced Liver Injury (DILI): | 0.963 | AMES Toxicity: | 0.026 |
| Rat Oral Acute Toxicity: | 0.791 | Maximum Recommended Daily Dose: | 0.029 |
| Skin Sensitization: | 0.033 | Carcinogencity: | 0.057 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
| Respiratory Toxicity: | 0.043 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003346 | ![]() |
0.883 | D0T5XN | ![]() |
0.293 | ||
| ENC005735 | ![]() |
0.738 | D07IPB | ![]() |
0.278 | ||
| ENC005736 | ![]() |
0.679 | D0C9XJ | ![]() |
0.270 | ||
| ENC005734 | ![]() |
0.673 | D07VLY | ![]() |
0.270 | ||
| ENC005727 | ![]() |
0.671 | D01XWG | ![]() |
0.268 | ||
| ENC005737 | ![]() |
0.665 | D01XDL | ![]() |
0.261 | ||
| ENC005730 | ![]() |
0.654 | D0Q0PR | ![]() |
0.246 | ||
| ENC000954 | ![]() |
0.654 | D0T8EH | ![]() |
0.245 | ||
| ENC000710 | ![]() |
0.654 | D01UBX | ![]() |
0.241 | ||
| ENC000983 | ![]() |
0.654 | D0FX2Q | ![]() |
0.236 | ||